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Background. Intensive behavioural counselling is effective for obesity, but resource requirements 
severely limit widespread implementation in primary care. We aimed to estimate the effectiveness and 
cost-effectiveness of an internet-based behavioural intervention with brief practice nurse support. 
Methods. POWeR+ is a 24 session web-based weight management intervention lasting 6 months. Adults 
with BMI>=30 (or >=28 with additional risk factors) were identified from UK GP records and sent postal 
invitations.  Following online  registration with POWeR+, patients were randomly allocated using 
computer generated random numbers by the website to either: 1) Control. An intervention which had 
previously demonstrated effectiveness: brief web-based information which minimised pressure to reduce 
foods, instead encouraging swaps to healthier choices and increasing fruit and vegetables, plus 6-monthly 
nurse weighing, or  2) POWeR+Face-to-face (POWeR+F) with face-to-face nurse-support (<=7 
contacts/6 months), or 3) POWeR+Remote (POWeR+R) with remote nurse-support (<=5 emails or brief 
phone calls/6 months). 
 Findings.  Weight loss averaged over 12 months (the primary outcome) was documented among 
666/818 (81%) participants. Analysis was intention to treat analysis using multiple imputation for 
missing data. The control group lost nearly 3 Kg (baseline 104.4, 6 months 101.9, 12 months 101.7). 
Compared with the control group POWeR+F achieved additional weight reduction of 1.5kg averaged 
over 12 months (95% confidence intervals 0.6 to 2.4, p=0.001) and 1.3kg for POWeR+R (0.34 to 2.2, 
p=0.007).  By 12 months 20.8% of the control group had maintained a clinically important 5% weight 
reduction, POWeR+F 29.2% (Risk ratio 1.56, 0.96 to 2.51, p=0.070), and POWeR+R 32.4% (1.82, 1.31 
to 2.74 ,p=0.004).  Health service costs of the intervention were low, and the incremental overall cost per 
kg weight lost compared to the control group was £18 (-129 to 195) for POWeR+F and -£25 (-268 to 
157) for POWeR+R. The probability of being cost-effective at a threshold of £100/kg lost was 88% and 
98% respectively.  No adverse events were reported. 
Interpretation. Weight loss was maintained for some individuals by promoting novel written materials 
with occasional brief nurse follow-up. However, more can maintain clinically important  and cost-
effective weight reduction with a web-based behavioural programme and brief remote follow-up.  
 
This work was funded by the Health Technology Assessment (HTA) Programme of the National Institute 
for Health Research  (NIHR). ISRCTN21244703 
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Background 
Obesity is a major threat to public health, the  prevalence is  rising1-3 and the vast majority of patients are 
managed in primary care4.  Systematic reviews5, including  from NICE4, advocate dietary and physical 
activity intervention supported by intensive behavioural techniques. The limited availability of high level 
dietetic and behavior-change expertise, nor time available for counselling and follow-up, make this 
challenging in the progressively resource–constrained primary care environment6. A  review of  
controlled trials in primary care  (but excluding those with >30% attrition at 12 months, which is 
common in studies of obesity) found little evidence of appropriately intensive behavioural counselling 
and suggested trained interventionists7.   
 
An alternative to a cadre of highly trained interventionists is to use the internet to help support behaviour 
change. Reviews suggest that automated interactive web-interventions without human input can achieve 
weight loss greater than no treatment or minimal interventions, but with too many small, short-term trials 
in volunteer samples, arguing the need for large, pragmatic trials with at least one year follow-up and 
assessing cost-effectiveness8 9. The trials identified by NICE mostly had expert lifestyle and behavioural 
input, and followed up patients intensively - on average 13 times per year during the first 12 months4. 
NICE found that estimates of cost-effectiveness were very sensitive to whether weight loss was 
maintained, but estimated that any intervention which cost less than £100 per kg lost if maintained in the 
longer term was likely to be cost effective.   Automated interventions may be enhanced by human 
support, but while intensive support improves web-based weight management10 we are aware of no 
studies examining the effectiveness of the brief support by primary care staff that is likely to be both 
more feasible and cost-effective. A recent review identified 9 studies comparing internet support with 
minimal intervention, but 2 had unusual populations (University staff; lactating women), and the only 
study to report fewer than 10 contacts by behavioural counsellors documented less than 1.5Kg  weight 
loss and high attrition at 12 months with only 49% of individuals followed-up11.  
 
Our objective was to perform a parallel group pragmatic randomised primary care trial to estimate the 
effectiveness and cost-effectiveness of a web-based behavioural weight management intervention 
(POWeR+) with either brief face-to-face nurse support or brief remote nurse support for obese patients 
managed in UK primary care.  To minimise drop-out  we chose an active control group promoting 
healthy eating that had previously been shown to result in modest weight loss (2%) compared to a generic 
advice booklet12. The primary outcome was weight reduction averaged over 12 months and a secondary 
weight outcome the proportion achieving a clinically important 5% reduction in weight.  
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Research methods 
 
Participants.  
Practices in Central and South England (around Southampton and Oxford) identified participants from 
their routine electronic records. Up to 100 patients from each practice were randomly chosen, and invited to 
a screening appointment. Patients could also be referred opportunistically from routine practice 
appointments.  
 
Inclusion criteria.  
Patients with BMI >=30 kg/m2 (or >=28 kg/m2 with hypertension or hypercholesterolaemia) documented in 
the GP case records4 were eligible.   
Exclusion criteria: major mental problems e.g. psychosis (difficulty completing outcomes); too ill or unable 
to change diet (e.g. severe LVF);  pregnancy; breast feeding; or perceived inability to walk 100 metres 
(physical activity difficult); another member of the household taking part, no regular access to the internet. 
. 
 
The POWeR+ web-based intervention 
POWeR+ is a theory and evidence-based intervention to teach patients self-regulation and cognitive-
behavioural techniques to form sustainable eating and physical activity habits for long-term weight 
management in a series of 24 web-based sessions designed to be used over 6 months with novel content, 
links to external content and email reminders. Patients initially choose either a low calorie eating plan or 
a low carbohydrate eating plan, but could change plans at any stage if they wished. (see Appendix 1 for 
full details).  
 
Randomisation in main trial, informed consent.  
During the screening appointment, informed written consent was taken. Participants were given details of 
how to login and register, whereupon participants were presented with baseline questionnaires, upon 
completion of which they were automatically randomised by the website using computer generated random 
numbers to one of three intervention arms: 
 
1) Control group: evidence-based dietetic advice and 6 monthly nurse follow-up.  Participants were 
taken to a set of 2 printable web-based pages with brief structured advice. This intervention was active 
since it was intended to help weight-loss: the materials were developed by the Institute of Food Research 
to provide attractive strategies to minimise the pressure to cut down favourite foods, but instead to swap 
less healthy foods for healthier choices (healthy foods swap sheet), or to increase fruit and vegetables (we 
used the NHS 5-a-day sheet). Our previous trial documented 1.2 Kg weight loss among patients with 
hypertension when compared with a generic advice booklet11. To enhance retention  participants were 
informed that this intervention had supported weight loss. Nurses arranged brief follow-up (5-10 minute 
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appointments) with sufficient time to measure weight at 6 months and 12 months, but not to provide 
explicit counselling. 
 
2) POWeR+F. Web-based intervention and face-to-face nurse support. The rationale for this 
intervention was to provide automated behavioural counselling, with just three scheduled (and four 
optional) face-to-face nurse support sessions, thus requiring substantially less health professional skill 
and time than the evidence based lifestyle interventions documented in the NICE review4 and hence 
much easier to implement in the NHS.  In addition to 6 monthly weighing, as in the control group, 
participants had 3 scheduled face-to-face appointments in the first 3 months and then up to 4 more during 
a further 3 months if needed (i.e. 6 months in total). Weight gain on two consecutive logins triggered an 
automated email to the nurse advising that the patient required further support, or patients could request 
additional support.  
 
3) POWeR+R: Web intervention and remote support.  The rationale here was to test whether even 
briefer professional support for the web intervention could be effective. Patients could access the same 
web-based intervention as in the face-to-face group. In addition to 6 monthly weighing, as in the control 
group, participants had 3 scheduled phone or email contacts and up to 2 optional phone/email contacts in 
the first 6 months (triggered by weight gain or patient request as in the face to face group). 
 
Changes to the protocol. 
The Trial Steering Committee (TSC) advised an increased the sample size to allow for clustering which 
required an extension to the planned recruitment period. To avoid losing data a repeated measures 
ANOVA for the principal continuous outcome (i.e. weight) was changed to mixed multivariable 
regression modelling. Actiheart monitors were planned for a randomised subset, but organising this at a 
time of intensive final follow-up became too difficult. Piloting suggested that intensive follow-up for 
anything but the primary outcome would increase drop-out, so efforts concentrated on weight. The final 
analysis plan, matching the clinical rationale for our original sample size, included a secondary weight 
outcome - the proportion maintaining 5% weight loss. This is very important clinically13 14 and facilitated 
direct comparison with a previous UK primary care trial15 which published after our study commenced.  
 
Outcome measures  
Primary outcome (specified in the funding protocol): Weight loss averaged over a 12 month period, 
measured lightly clothed, without shoes, where possible at the same time each day, using automated Tanita 
digital scales.  
Secondary weight outcome:  maintenance of 5% weight loss. 
Other outcomes. There was no explicit measurement of the ‘work’ of participants when, but we report 
health service resource use, usage of the website (pages accessed and time taken, recorded automatically by 
the website), and how enabled patients felt (using the modified Patient enablement instrument16), and the 
additional activities participants used to help lose weight. A range of other secondary measures were also 
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documented (waist measurement, blood pressure, HBA1C, liver function tests; self-report measures of 
physical activity, diet, see Appendix 4 for detail).   
 
Outcomes/data collection (at baseline and unless specified at 6 and 12 months). Participants had 
appointments for weight measurement with the practice nurse at baseline and 6 months, and at 12 months an 
appointment or home visit by a nurse researcher blinded to group. Where a blinded weight measurement 
could not be obtained we used practice nurses’ recorded weights, and where that was not possible we used 
participants’ reported weight. For self-report measures there were three emails prompting online completion 
followed by a postal version of the questionnaire. 
 
Sample size.  
We compared each of the intervention groups primarily with control but also potentially with each other 
so allowed for alpha=0.017 (i.e. 0.05/3). For the primary outcome (weight) we estimated that a 
standardised effect size of 0.33 (equivalent to 2-3 kg difference assuming an SD of  change of 6.5-7.5 
kg17 18) and 80% power required 174 patients per group with complete data, or 654 patients in total 
allowing for 20% loss to follow-up. Following liaison with both the funder (HTA) and the TSC the power 
calculation was revised to allow for modest clustering at practice level if significant clustering was found. 
We assumed recruitment of 18 patients per practice to achieve 15 patients at follow-up, of whom roughly 
5-6 would be in each of the two intervention groups at follow-up. Assuming 5 per group in each practice 
for an ICC (intra-cluster correlation) of 0.05 i.e. a design effect 1.2 (1+ ((5-1)x0.05)) this resulted in a 
minimum of 654*1.2=785 patients. 
 
Statistical analysis.  
The primary analysis. Mixed multivariate regression models were chosen to enable data to be used from 
anyone who had 6 months or 12 months data. We modelled the risk ratios compared with the control 
group for the number achieving 5% weight loss. All regression models controlled for weight at baseline, 
sex, age, smoking, diabetes, medications (including Orlistat used at baseline), any comorbidities, 
deprivation (IMD2010) and any clustering by practice. No interim analyses were undertaken as per the 
approved study protocol. 
Missing data. Loss to follow-up was fairly similar between arms which reduces the potential impact of 
data not following the missing at random assumption. Nevertheless, intention to treat analysis used both 
measured and reported weights in a multiply-imputed data set (based on 50 replications).  Secondary 
analyses were of complete cases, and also just using measured weights – both of which analyses 
documented slightly larger effect sizes. 
Subgroup analyses: We explored whether there was significant effect modification in subgroups using 
interaction terms in the models.  Key subgroups identified in advance were: baseline waist measurement 
(high or very high waist vs low waist: men high 94cm, very high 102cm; women high 80cm, very high 
88cm), and the presence of the metabolic syndrome (syndrome vs no syndrome).  The metabolic 
syndrome19 was defined as 3 out of 5 of elevated waist  circumference (<94cm for men, 80 for women), TG 
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>=1.7 mmol/l, reduced HDL-cholesterol (<1.00 mmol/L in males <1.3 mmol/l in females) BP (SPB >130 or 
diastolic >85, or treatment of high BP) elevated fasting glucose >= 5.6 mmol/l.20 We also explored 
outcomes according to the type of diet chosen by patients.  
 
Economic evaluation 
Health service resource use data (see Appendix 2 for more detail) were collected through case notes 
review covering medication, primary care visits, outpatient consultant, A+E and hospital admissions 
associated with obesity (the management of obesity, and conditions affected by obesity such as 
cardiovascular disease, control of asthma, and musculoskeletal problems (hip, back and knee)). Outcomes 
were measured as incremental costs per Kg weight loss. We have applied multiple imputation for missing 
values and applied bootstrapping to the imputed data to produce confidence intervals for the cost-
effectiveness analyses.  
 
Trial registration and ethics 
The trial was registered on 16/3/12 as an International Standard Randomised Controlled Trial 
(ISRCTN21244703) and ethics approval given by NRES Committee South Central Southampton B First 
MREC (approval date 19/12/2011, reference: 11/SC/0455). A £10 gift voucher was sent out with the 12 
month appointment notification letter as a thank you for participation irrespective of whether an 
appointment was made. 
 
Role of the funding source 
This project was funded by the Health Technology Assessment (HTA) Programme  of the NIHR (study 
reference 09/12/19, 11939).  FDRH was part-supported by the NIHR School for Primary Care Research, 
NIHR Oxford Biomedical Research Centre, and NIHR Collaboration for Leadership in Applied Health 
Research and Care Oxford. CDB is part-funded  by the Southampton NIHR Biomedical Research Centre. 
The University of Southampton was the Sponsor, but neither the funder nor the sponsor had roles in the 
running of the study, the analysis, the write-up, nor the interpretation of the results.  
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Results  
 
818 eligible individuals from 56 practices were randomised from January 2013 to March 2014.  Of these, 
407 had a weight recorded at the 6 month follow up and 666 had a weight recorded at 12 months.  Of the 
666, 510 (76.7%) were blinded weights, 28 (4.2%) unblinded weights and 128 (19.2%) reported weights.  
The number with reported weights were similar in each group (Control n=40, POWeR+F n=48, 
POWeR+R n=40). Table1 shows the baseline characteristics of the groups, which were mostly well 
balanced. The practice intra-cluster correlation (icc) for weight in the repeated measures analysis was 
0.01 (95% confidence intervals 0.003 to 0.09) when controlling for baseline weight. 
 
Intervention receipt. 
Of the 539 participants randomised to the POWER+ intervention groups, 524 started the first session and 
404  completed all 3 core sessions (196  of the remote support group and 208   of the Face-to-face support 
group). Participants completed an average of 10.97 (SD=12.65) weight and goal reviews (range 0-52); the 
average was 10.16 (SD=11.92) in the Face-to-face group and 11.85 (SD=13.38) in the Remote support 
group.  The median number of nurse contacts was 4 (range 0 to 7) in both intervention groups, with a 
median of 2 face to face, 1 phone and 1 email contact in the POWeR+F group, and a median of 1 phone 
call and 3 emails in the POWeR+R group. There was around 2-2.5 kg difference in weight reduction for 
those who completed more than the first basic stage of the Programme. 
 
Outcomes 
Mean weight reduction: The active control group maintained a weight loss of nearly 3 kg  over 12 
months (baseline 104.4 Kg (n=279), 6 months 101.9 Kg (n=136), 12 months 101.7 Kg (n=227) (Table 2).  
The primary imputed analysis (Table3) documented that compared to the control group the face to face 
support group achieved an estimated additional 1.5 kg reduction averaged over the 12 months period (-
2.4 to -0.6, p=0.001) and the remote group an additional 1.3kg reduction (-2.3 to -0.3, p=0.005). A 
secondary analysis of just the complete cases over 12 months documented greater weight reduction 
compared to the control group: Face-to-face -1.78 kg (-2.8 to -0.8), Remote -1.6 kg (-2.6 to -0.6) (see 
Tables 8 and 9, Appendix 3). 
 
Clinically important weight maintenance: By 12 months using data from complete cases 18.5% (42/227) 
of the control group had maintained a 5% or more reduction in weight, POWeR+Face-to-face 28.1% 
(62/221) and POWeR+Remote 31.7% (69/218). The imputed estimates were  respectively 20.8%, 29.2%, 
and  32.4% (Table  4).   
 
NHS resource use and other activities.  
 
753 casenotes were reviewed from the GP electronic records for 12 months after recruitment. The mean 
intervention costs per person using the services  were low (£22 for POWeR+F and  POWeR+R £12), or 
for all participants in each group £17 and £9 respectively. Adding the estimated cost of the web raised 
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these to £18  and £10  respectively.  Bigger differences in costs were found in estimating overall NHS 
resource use related to obesity (see Table 7b). If bootstrapping is used the estimate of the differences in 
costs compared with the control group for POWeR+ Face-to Face is £23 (-105 to 152) and for 
POWeR+Remote -£36 (-154 to 81).  None of these differences were statistically significant. The 
estimated incremental overall NHS cost per kg weight loss was  £18 (-129 to 195) for POWeR+F, and -
£25 (-268 to 157) for POWeR+R. i.e. POWeR+R dominated the control group since it was more effective 
and cost less (see Table 5). The cost-effectiveness acceptability curves put the probability of being cost 
effective at well over 80% for both interventions (88% and 98% respectively) compared with the control 
group (see Appendix 2 for more details). 
 
For those returning the final questionnaire almost half the people in the control group (47.1%; 64/136) 
were doing something else to help lose weight as opposed to 37.2% (51/137) in the Face-to-Face group 
and only 26.7% (40/150) in the Remote group (Table 6). Participants also felt more enabled to manage 
their weight problem in the POWeR+ groups (Table 6). 
 
Subgroups  
There was some evidence of a lesser effect of the POWeR+F group at 6 months among participants with 
the metabolic syndrome, but no significant impact of type of diet chosen (see Appendix 3 for more 
detail).  
 
Secondary outcomes   
Due to the priority to obtain follow-up for weights, and the clear feedback from piloting that pressurising 
participants to have blood taken was off-putting, achieving high follow-up for blood samples was 
necessarily a secondary priority for the trial team, and so a minority of participants had follow-up blood 
measurements. As a result, even though estimates use multiple imputation, the results for blood samples 
must be interpreted cautiously. What results are available suggest generally positive directions of 
outcomes in the POWeR+ groups, albeit mostly not statistically significant  (raised HDL cholesterol, 
lower AST and ALT, lower HbA1C; see Appendix 4 tables 10 to 12). The low completion rate for EQ5D  
makes this data less reliable, so the interpretation of the direction of change of EQ5D is difficult to 
interpret, particularly as the estimate of the direction of change varies depending on whether baseline 
values are controlled for (tables 17 and 18). 
 
Fat mass and blood pressure were recorded in the majority of participants at follow-up (in both cases 
more than 450 individuals) and although there were no consistent changes in blood pressure, fat mass 
reduced slightly in both POWeR+ groups (Appendix 4 table 13).  
 
Harms. No harms were reported during the study 
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Table 1. Baseline characteristics*  
 
 Control group: 
Brief verbal and online 
healthy eating advice 
POWeR+ Face-to-face  
(Access to website and 
brief face to face support) 
POWeR+ remote: 
(Access to website and 
brief remote support) 
Female (n) (%) 185/279 (66.31%) 175/269 (65.06%) 160/269 (59.48%) 
Age (y) 52.69 (13.25)  53.70 (13.21)  54.74 (12.95) 
Smoker (n) (%) 24/279 (8.6%) 21/269 (7.81%) 25/269 (9.29%) 
Diabetes (n) (%) 48/279 (17.20%) 46/268 (17.16%) 42/270 (15.56%) 
Orlistat use (n) (%) 3/270 (1.11%) 5/262 (1.91%) 5/266 (1.88%) 
Comorbid condition (n) 
(%) 
48/281 (17.08%) 55/269 (20.45%) 55/272 (20.22%) 
Deprivation score (Index 
of Material Deprivation 
score 2010) 
14.32 (10.45)  13.73 (10.28)  13.29 (10.17)  
Weight (kg)  104.38 (21.11)  102.40 (16.87)  102.93 (18.26)  
Body Mass Index (kg/m2) 37.10 (5.97)  36.66 (5.36)  36.28 (5.65)  
*Mean (S.D.) unless indicated 
 
Table 2. Crude mean weights for complete cases at baseline, 6 and 12 months 
 Mean weight in kg (s.d.) 
 Baseline 6 months 12 months 
Control group: 
Brief online and verbal 
healthy eating advice 
104.38 (21.11) n=279 
 
101.91 (19.35) n=136 101.73 (19.57) n=227 
POWeR+Face-to-face  
(Access to website and 
face to face support) 
102.40 (16.87) n=269 97.55 (15.99) n=148 98.56 (15.95) n=221 
POWeR+Remote: 
(Access to website and  
brief remote support) 
102.93 (18.26) n=270 98.30 (18.34)  n=155 99.72 (18.88)  n=218 
 
Table 3. Imputed data based on 50 imputations – difference in weight loss (kg) compared to control 
group 
 
 Difference in weight loss compared to the control group (95% confidence intervals) 
 6 months 12 months Over study period (repeated 
measures) 
Face-to-face -2.54 (-3.66, -1.42; p<0.001)  -0.37 (-1.66, 0.92; p=0.566)  -1.49 (-2.41, -0.58; p=0.001)  
 
Remote -1.97 (-3.18, -0.76; p=0.002)  -0.58 (-1.88, 0.72; p=0.375)  -1.27 (-2.19, -0.34; p=0.007)  
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Table 4. Proportions maintaining at least 5% weight loss at 6 and 12 months  
 
  
Proportion losing at 
least 5% of baseline 
weight or more – 
compete cases 
 
Risk ratio of achieving 
weight loss of 5% of 
baseline weight or 
more compared to the 
Control group – 
complete cases 
 
 
Proportion losing at 
least 5% of baseline 
weight or more – 
imputed data 
 
Risk ratio of achieving 
weight loss of 5% of 
baseline weight or 
more compared to the 
Control group – 
imputed data 
 6 months 12 months 6 months 12 months 6 months 12 months 6 months 12 months 
Control 16/136 
(11.8%) 
42/227 
(18.5%) 
1.00 1,00 15.9% 20.8% 1.00 1.00 
POWeR+F 59/148 
(39.9%) 
62/221 
(28.1%) 
3.42 
(2.10, 
5.56; 
p<0.001)  
1.46 
(1.02, 
2.08; 
p=0.036)  
36.8% 29.2% 3.10 
(1.85, 
5.18; 
p<0.001)  
1.56 
(0.96, 
2.51; 
p=0.070)  
POWeR+R 55/155 
(35.5%) 
69/218 
(31.7%) 
3.02 
(1.89, 
4.83; 
p<0.001)  
1.67 
(1.17, 
2.37; 
p=0.004)  
33.7% 32.4% 2.64 
(1.60, 
4.36; 
p<0.001)  
1.82 
(1.21, 
2.74; 
p=0.004)  
 
 
 
Table 5. Incremental overall NHS cost per Kg weight lost (ICER) compared with the control group 
based on the imputed data using repeated measurement  
 
 
Group vs. group Mean difference of 
costs in £(95% CI) 
Mean  of weight lost 
(kg)  (95% CI) 
Incremental cost (£) per 
weight lost (95% CI) 
POWeR+F vs. Control 
group 
23 (-105, 152) 1.49  (0.58, 2.41) 18 (-129, 195) 
POWeR+R vs. Control 
group 
-36 (-154, 81) 1.27 (0.34, 2.19) -25(-268, 157)  
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Table 6. Additional activities undertaken over 12 months, and patient enablement in managing 
their weight 
 Control 
(n (%)) 
Face-to-face 
(n (%)) 
Remote 
(n (%)) 
Additional activities     
Take part in regular activity long enough 
to work up a sweat 
   
- Rarely 50/135 (37.0%) 38/134 (28.4%) 39/146 (26.7%) 
- Sometimes 57/135 (42.2%) 69/134 (51.5%) 77/146 (52.7%) 
- Often 28/135 (20.7%) 27/134 (20.2%) 30/146 (20.6%) 
Take part in another weight loss activity 64/136 (47.1%) 51/137 (37.2%) 40/150 (26.7%) 
Of these the reported activities were:     
Weightwatchers/Slimming World (or 
similar) meetings 
23/136 (16.9%) 22/137 (16.1%) 14/150 (9.3%) 
Another weight management website 0/135 (0.0%) 4/136 (2.9%) 4/150 (2.7%) 
Phone app 13/136 (9.6%) 8/136 (5.9%) 10/149 (6.7%) 
Weight loss pills 5/136 (3.7%) 4/137 (2.9%) 2/150 (1.3%) 
Health trainer program 4/136 (2.9%) 2/136 (1.5%) 3/148 (2.0%) 
Exercise referral scheme 4/136 (2.9%) 7/137 (5.1%) 4/148 (2.7%) 
Another weight loss scheme 8/136 (5.9%) 13/136 (9.6%) 8/149 (5.4%) 
Any other weight management method 22/97 (22.7%) 13/87 (14.9%) 8/103 (7.8%) 
    
Patient enablement     
Mean Item score at baseline (SD) 3.19 (1.27)  
 
3.42 (1.19)  3.31 (1.26) 
Mean Item score at 12 months (SD) 3.23 (1.57)  
 
4.10 (1.28)  
 
3.85 (1.35) 
Difference in enablement score 
compared to control group  
(95% confidence intervals) 
 0.70 (0.39, 1.01; 
p<0.001)  
 
0.54 (0.24, 0.85; 
p<0.001) 
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Discussion. 
 
This is one of few studies comparing simple weight management interventions using primary care staff 
for support to manage obesity. Clinically important weight loss was achieved by some participants in the 
active control group, and the mean weight reduction at the end of 12 months was not significantly less 
than the POWeR+ behavioural web-based intervention groups. However in the POWeR+ groups 
significantly more weight loss occurred averaged over 12 months, by 12 months more participants 
maintained clinically important weight reduction, and more patients felt enabled to manage their weight. 
With brief nurse remote support for POWeR+ this was achieved without increasing health service costs. 
 
Strengths and limitations. 
The individuals who take part in trials are likely to be a relatively well-motivated group, but this is also 
the intended target group where intervention is most likely to be helpful. The study was large and 
pragmatic, mimicking the everyday conditions in primary care settings, which had the disadvantage that 
the control group were not closely controlled, and so they undertook other activities to lose weight. This 
is also a strength as estimates are more realistic - since this would happen in practice. Participants with 
obesity in primary care settings are notoriously difficult to follow-up, but we achieved follow-up of more 
than 80% of individuals at 12 months. Loss to follow-up was similar between arms, which reduces the 
impact of missing data. Furthermore, we have reported the primary analysis using the imputed data,  
which provides more conservative (i.e. smaller) estimates of effectiveness than complete cases. However, 
in practice multiple imputation modified the estimates only slightly - which suggests that attrition bias 
was not a major issue. Based on the experience of piloting, where pressure to achieve follow-up of both 
primary and secondary outcomes resulted in participants dropping out, our effort concentrated on 
maximising the primary outcome, which resulted in fewer secondary outcomes being available. The fact 
that we found significant weight loss irrespective of the method of specifying the weight outcome 
(average reduction over 12 months as specified in the funding application, or clinically important weight 
loss at 6 or 12 months), and that most secondary outcomes also changed in positive directions albeit 
mostly not significantly, makes selective reporting and type I error less likely. 
 
Main findings put in context of existing literature. 
Our observation of 3% loss in weight in the active control group, and the maintenance of clinically 
important weight loss in 11.8% and 18.5% of participants at 6 and 12 months respectively, was consistent 
with our previous findings12 – i.e. that a brief intervention promoting the use of simple sheets for food 
swaps and five-a-day fruit and vegetable consumption helps with weight control. Some of the effective 
weight management in this group may also be due to the motivational effects of regular follow-up 
weighing by the nurse, and undertaking other activities to help themselves (which about 50% did). In 
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contrast, fewer individuals offered the POWeR+ interventions undertook other activities, and they felt 
significantly more enabled to manage their weight.  
 
Systematic reviews of interventions in other settings and primary care suggest that both intensive dietetic 
behavioural counselling and intensive follow-up are usually necessary to achieve effective weight 
reduction4 7 21. In contrast, we found that a behavioural web-based intervention such as POWeR+ was 
effective with just a few brief phone calls and emails plus 6 monthly weighing. The weight loss achieved 
with POWeR+ compares favourably with other internet-based interventions, which on average22 (albeit 
with high heterogeneity) have led to only short term weight loss, of less than 1kG weight loss compared 
to no treatment controls, or less than 2KG if combined with face-to-face support - based on a review of 
predominantly motivated volunteer samples22. Better weight management results using an internet-based 
programme (around 5Kg) have only been achieved with much more intensive human support (for 
example, weekly 20 minute contact for 12 weeks, and then monthly up to 24 month follow-up109). 
Encouragingly, the weight loss achieved by POWeR+ was comparable to the best performing 
interventions15 23 evaluated over 12 months in a primary care setting, including those produced by face-to-
face commercial programmes. Controlling for deprivation made no difference to the estimates and there 
was also no interaction with deprivation. 
 
The estimates of resource use suggest that both interventions were not very resource intensive. 
Considering overall NHS costs, fewer NHS resources were used in the Remote group, mainly due to 
reduced primary care costs. Given the variability of cost estimates, these results must be treated with 
some caution, but it seems unlikely that health service costs will be significantly increased with the 
Remote intervention. We also found that POWeR+ users felt significantly more enabled to manage their 
condition, so it is plausible that if individuals can be enabled to manage their own condition without 
needing significant face-to-face contact, this could empower self-management more generally. Previous 
modelling by NICE demonstrated that cost-effectiveness is very sensitive to whether weight loss is 
maintained but that at least a 1 kg per head weight loss among overweight or obese adults is likely to be 
cost effective if is maintained, provided that the cost per person of intervening is less than £100. The 
current results suggests that irrespective of whether intervention costs or overall costs are used both 
interventions achieve weight losses at a cost per kg below that required by NICE4. The  POWeR+ 
intervention was for 6 months but the number maintaining clinically important weight loss remained 
steady to 1 year which suggests longer term benefit could be achieved. However, since weight loss may 
not be maintained after 1 year, future research should assess the extent to which clinically important 
weight loss can be maintained beyond one year. 
 
Conclusion. A web-based behavioural weight management programme (POWeR+) with brief remote 
follow-up is  effective, helps participants feel more enabled to manage their weight, provides comparable 
results to the best performing interventions evaluated in  primary care settings including commercial 
programmes, and is likely to be cost-effective. 
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. 
.Research  in context.  
Previous evidence. The most recent systematic review published by Hutcheson et al included studies of 
adults aged ≥18 years assessing weight loss or weight maintenance interventions using an e-Health 
component. Eight databases were searched (The Cochrane Library, MEDLINE/PREMEDLINE, 
EMBASE, CINAHL, Web of Science,Scopus, PubMed, and PsycINFO) from 1995 to 17 September 
2014. The search terms were obesity/ or obesity, abdominal/ or obesity, orbid/Overweight/Adiposity/ 
obese.mp.ehealth.mp.  or telemedicine/ telehealth.mp.Text Messaging/mhealth.mp.Computers, Handheld/ 
(tablet* and (mac or ipad or android* or microsoft or windows)).mp. [mp=title, abstract, original title, 
name of substance word, subject heading word, keyword heading word, protocol supplementary concept, 
rare disease supplementary concept, unique identifier]exp Internet/world wide web.mp.web based.mp. 
((web* or remote or online) adj3 deliver*).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier]website*.mp.online.ab,ti.smart phone*.mp.digital 
game*.mp.smartphone*.mp.Computer Simulation/ or virtual reality.mp. exp diet/healthy 
eating.tw.nutrition.tw.physical activity.tw.exp exercise/*motor activity/*Physical Fitness.                                      
The quality (risk of bias) for twenty-three (27.4%) of studies were classified as higher quality, 67.9% (n = 
57) moderate quality and 10.7%(n = 9) lower quality.                                                                                       
Meta-analysis demonstrated significantly greater weight loss (kg) in eHealth weight loss interventions 
compared with minimal interventions (MD−1.40 [−1.98,−0.82], P < 0.001. However, of the 9 studies, 2 
had unusual populations (University staff; lactating women), and the only study to report fewer than 10 
contacts by behavioural counsellors documented less than 1.5Kg  weight loss and high attrition at 12 
months with only 49% of individuals followed-up. Thus there is poor evidence for the effectiveness for 
internet interventions utilising brief behavioural support in a primary care setting.  
What this study adds. Our results fill this gap by demonstrating that clinically important weight 
reduction is possible with a web-based behavioural programme lasting 6 months combined with brief 
remote follow-up (achieving approximately 1.5 Kg more weight loss than an active control intervention 
and  30% maintaining 5% weight loss by 12 months), with less recourse to other weight loss activities 
and is likely to be cost-effective. 
Implications of all the available evidence. The weight loss achieved by POWeR+ was comparable 
to the best performing interventions evaluated in a primary care setting over a 12 month period, including 
those produced by face-to-face commercial programmes. 
Implications for practice. The POWeR+ Programme when combined with very brief staff support could 
be feasibly used in most practices and make a clinically important contribution to the management of 
obesity.  
Future research. Since weight loss may not be maintained after 1 year, future research should assess the 
extent to which clinically important weight loss can be maintained beyond one year. 
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Figure 1. CONSORT Diagram 
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Appendix 1 
Intervention description:  POWeR+ 
 
Positive Online Weight Management Plus (POWeR+) is an automated online intervention to support 
weight management over one year. POWeR+ was developed  from the initial 12 session POWeR 
intervention, which was subject to a feasibility trial24.  It was adapted from an earlier version (POWeR) 
which was extensively trialled and shown to improve weight loss. Development was informed by the 
Person-Based Approach (PBA)25 which employs an iterative process of in-depth qualitative user testing, 
and a theoretical basis involving the principles of self-determination theory28 and techniques from 
cognitive behavioural theory26. The Person-Based Approach was used for development to maximise 
acceptability, feasibility and engagement 25 27 28. 
 
POWeR+ was designed to provide support for sustainable long-term self-management of weight. Patients 
choose either a low calorie eating plan (a reduction of around 600 calories a day) or a low carbohydrate 
eating plan (a carbohydrate limit of 50g a day).  Users can base their eating plan on a traffic light system 
that categorises foods into those that could be eaten freely (‘green’), in moderation (‘orange’) or very 
sparingly (‘red’). The low carbohydrate eating plan categorises most vegetables and some fruits as 
‘green’ and only categorises very high sugar and starchy foods as ‘red’ and is therefore compatible with a 
sustainable healthy diet. Patients are also encouraged to increase their physical activity levels by choosing 
either a walking plan (in which case they can request a pedometer) or a self-selected mixture of other 
physical activities.  
 
POWeR+ focuses principally on fostering users’ self-regulation skills for autonomously self-managing 
their weight, rather than providing detailed dietetic advice. Throughout POWeR+, users are taught active 
cognitive and behavioural self-regulation techniques (‘POWeR tools’) to overcome problems such as low 
motivation, confidence or relapse. Evidence is provided for the effectiveness of these techniques and 
examples given of how others have successfully used them (‘POWeR stories’). POWeR+ emphasises 
forming healthy eating and physical activity habits that should become non-intrusive and require little 
effort to sustain. POWeR+ is tailored by gender, using language and ‘POWeR stories’ designed to appeal 
to men and women.  
 
The intervention was developed based on behavioural theory and evidence from existing successful 
interventions, with very extensive iterative qualitative piloting with a wide range of users from the target 
population to check usability, accessibility and acceptability and to elicit and respond to user views. 
Further details of the intervention development and early evaluation are given elsewhere 24 27 29-31. Aspects 
of POWeR+ that were modified from the original POWeR intervention included; use of game-based 
techniques (i.e. sessions grouped into stages that the user advances through), addition of extensive novel 
content (extra sessions to maintain interest for a longer period), shorter sessions (to enhance 
engagement), and improvements to usability and navigation.   
 
Participants were encouraged to continue to use the website weekly to track their weight, set and review 
eating and physical activity goals, and receive personalised advice. After entering their weight and 
whether they had achieved the goals they had set themselves the previous week, patients received tailored 
feedback giving encouragement if maintaining weight loss (e.g. reminders of health benefits accrued) and 
meeting goals. Weight gain and failing to meet goals triggered automated personalised advice such as 
appropriate goal-setting and planning, boosting motivation, overcoming difficulties, recovering from 
lapses.  
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Overview of the 4 stages of POWeR+ 
 
Stage 1: Users are tunnelled (i.e. they cannot proceed to a session until they have completed the previous 
session) through 3 core sessions introducing them to POWeR and guiding them through the process of 
setting and reviewing weekly goals (see figure 1). There are 3 components to the goal review: 
- Recording weight 
- Choosing an eating plan from: 
o A low calorie diet 
o A low carbohydrate diet  
- Choosing a PA plan 
o Increasing walking using a provided pedometer and recording the weekly step count.  
o Choosing any other physical activity and setting weekly goals 
Participants may opt to change their plans after their weekly goal review at any point during the 
intervention. 
 
Stage 2: Users have free choice access (i.e. they can access the sessions in any order) of sessions 4-10. 
Goals can now be reviewed weekly and users can view their progress on a graph. If a user misses a week 
of goal review, they may still review their goals the following week. After all sessions are completed or a 
period of 7 weeks has passed since the stage was started, stage 3 sessions become available.  
 
Stage 3: Users have free choice access to sessions 11-17 and continue complete weekly goal reviews. 
After all sessions are completed or a period of 7 weeks has passed since the stage was started, stage 4 
sessions become available.   
 
Stage 4: Users have free choice access to sessions 18 – 25 and continue to complete weekly goal reviews.  
Throughout the intervention, weekly emails are sent to remind users to complete their goal review. Set 
periods of inactivity at various points during the intervention also trigger emails prompting users to return 
to either complete sessions or their goal review.  
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Overview of POWeR+ stages and session titles 
 
Stage 1 (user is tunnelled through these sessions) 
Session 1 pt 1 Introduction to POWeR 
Session 1 pt 2 Introduction to goal setting and weekly weighing 
Session 2 Getting support from other people 
Session 3 Physical activity 
Stage 2 (free choice sessions. These are unlocked once user completes session 3) 
Session 4 Setting the strongest plans – mini session  
Session 5 Controlling your cravings 
Session 6 Stretching your physical activity 
Session 7 Setting up your environment to help you lose weight 
Session 8 Dealing with slip ups 
Session 9 How to break bad habits – mini session  
Session 10 How to develop your new healthy identity – mini session 
Stage 3 (free choice sessions unlocked once user completes stage 2 or after 7 weeks) 
Session 11 Eating when times are tough 
Session 12 Eating out 
Session 13 Being drink aware 
Session 14 Take on a physical activity challenge – mini session  
Session 15 A quiz to show you which tricky situations you are best at dealing with, and which 
you still need to work on – mini session 
Session 16 Winning against temptations – mini session 
Session 17 When losing weight gets hard – mini session 
Stage 4 (free choice sessions unlocked once user completes stage 3 or after 7 weeks) 
Session 18 Using mindfulness to help you lose weight 
Session 19 Getting support from your family – mini session 
Session 20 Have you made your changes into habits? Take this quiz to find out – mini session 
Session 21 Make new habits easier, by linking them to things you already do – mini session 
Session 22  A quick, easy tool to stop stress spoiling your weight loss – mini session  
Session 23 Busy lives 
Session 24 Maintaining your weight loss – we recommend you complete this session last 
Session 25 Successful celebrations(only available from the ‘tools’ page) 
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Figure 1: Overview of weekly goal review 
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Appendix 2.   
 
The costing (summarised in Table 7) comprised two elements: one measuring the intervention cost alone, 
based on the cost of internet plus that of nurse support. The other was total cost i.e. the cost of the 
intervention plus differences in cost of NHS services related to obesity. The perspective was that of the 
NHS and personal social services.  The time horizon was 12 months.   
 
The main costs of the intervention were nurse supporting time in terms of face to face consultations, 
telephone or email contact. The cost of nurse support was based on trial data on the number of contacts by 
type (face-to-face, telephone and email, all with the practice nurse). Face-to-face contacts linked to the 
trial interventions were planned to last half as long as normal visits.  These were assumed to cost 50% of 
standard practice nurse consultations1.The time taken for telephone contacts relative to face to face to 
visits was  based on the split provided for GPs between face to face and other contacts in PSSRU unit 
costs. The time taken for email contacts was set at 50% that of telephone contacts. These were all costed 
using national costs per consultation for a practice nurse (PSSRU, 2013/14). The unit costs used in costing 
the intervention are shown in the table below. 
 
The cost of the intervention comprised the cost of the web site and the support offered to users. The 
development costs of providing a web intervention that could be used very widely would be spread 
among thousands of individuals. We estimated the cost of the website at £1 per person using it, mainly 
due to the cost of providing and maintaining the website. No cost has been applied to those using the site, 
but not having access to the intervention. Although pedometers were offered to participants in the 
POWeR+ groups (costing £10),  the impact was modest, and since starting the study pedometer apps for 
mobile phones have become widely available for the target population. Thus we anticipate that in 
implementing the intervention no offer of pedometers would be made, hence our base case assumption 
does not allow for the cost of pedometers. Even if we assume that the additional £10 is a necessary part of 
the intervention this would still leave the intervention costs per Kg lost at well under £100/kg, and so 
does not alter the inferences. 
 
The cost of the control group with brief verbal intervention and supporting advice sheets was not costed 
specifically but assumed to be part of primary care consultations. Resource use data were extracted from 
GP case-notes 12 months after recruitment covering medication, primary care visits, outpatient consultant, 
A&E attendance and hospital admission. Intervention-specific resource use was recorded by study nurse.  
 
Data collected covered medications plausibly associated with obesity: diabetes, blood pressure, 
clotting/antiplatelet, diabetes, musculo-sekeletal problems (back, hip and knee pain), lipid lowering and 
weight management. The names of these medications, dosage, and days of use were recorded.  Prices 
were the listed pack price, the cost to the NHS. If a drug was started before the trial starting data and 
when no ending date was recorded, we assumed that the duration of such use as the length of the trial (12 
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months). For rest of the medications, if no duration of use was available, the actual and recommended 
duration the number of packs was estimated from the starting data of the medication.  The unit costs of 
medications were obtained from the British National Formulary (BNF) in 2013-2014 prices (British 
National Formulary http://www.bnf.org).Consultations in primary care, walking in centre, A&E and 
outpatient attendances were recorded and priced using PSSRU 2013/4 unit costs. 
 
Data on all hospital admissions were also extracted.  We used HRG cost per episode for hospitalisation-
specific causes of admission 2013/4 (Department of Health (2014) NHS Reference Costs 2013 to 2014. 
https://www.gov.uk/government/publications/nhs-reference-costs-2013-to-2014). Data on these unit costs 
and those for medications are available on request.  
 
 
 
Table 7a Summary of the intervention specific nurse support : mean number of contacts by type 
 
 
Intervention 
groups  
Contacts Mean (95% CI)   Mean (95% CI)    
  Mean for those using the 
service 
Mean for all 
POWeR+ F 
N=269 
face to face 2.33 (2.17, 2.49) n=173 1.5 (1.33, 1.67) 
Email 2.13 (1.91, 2.35) n=116 0.92 (0.76, 1.08) 
Phone 1.82 (1.6, 2.03) n=120 0.81 (0.67, 0.95) 
Total  4.5 (4.25, 4.74) n=193 3.23 (2.93, 3.53) 
POWeR+R 
N=270 
face to face 1.56 (1.13, 1.98) n=18 0.1 (0.05, 0.16) 
Email 3.13 (2.94, 3.32) n=173 2 (1.79, 2.22) 
Phone 1.62 (1.47, 1.77) n=124 0.74 (0.63, 0.86) 
Total 4.25 (4.05, 4.46) n=181 2.85 (2.58, 3.13) 
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Table 7b  Mean obesity-related NHS resource use in each group (2013/2014 prices) 
Groups   Categories  Means (95% CI ) for those 
using service 
Mean for All (95% CI ) 
Control 
group 
N=259 
Cost (£) All costs 428 (320, 537) n=259 428(320, 537) 
Medication 271 (191, 350) n=119 124(85, 164) 
GP consultation 72 (60, 83) n=142 39(32, 47) 
Outpatient 
attendance 
548 (388, 709) n=49 104(64, 143) 
Hospital admission 2569 (1158, 39805) n=11 109(28, 190) 
Number 
of cases 
Medication usage 3.23 (2.84, 3.62) n=119 1.48(1.22, 1.75) 
GP consultation 2.68 (2.33, 3.03) n=142 1.47(1.22, 1.72) 
Outpatient 
attendance 
4.06 (2.87, 5.25) n=49 0.77(0.48, 1.06) 
Hospital admission 1 (1, 1) n=11 0.04(0.02, 0.07) 
POWeR+F 
N=250 
Cost (£) All costs 431 (319, 543) n=250 431(319, 543) 
Medication 191 (150, 232) n=140 107(81, 133) 
GP consultation 83 (67, 97) n=148 49(39, 59) 
Outpatient 
attendance 
534 (373, 695) n=47 100(61, 140) 
Hospital admission 3986 (1840, 6132) n=7 112(18, 205) 
Nurse support 22 (21, 23) n=193 17(15, 18) 
Number 
of cases 
Medication usage 2.84 (2.55, 3.13) n=140 1.59(1.35, 1.83) 
GP consultation 2.74 (2.37, 3.11) n=149 1.63(1.36, 1.91) 
Outpatient 
attendance 
3.96 (2.76, 5.15) n=47 0.74(0.45, 1.03) 
Hospital admission 1.43 (0.7, 2.16) n=7 0.04(0.01, 0.07) 
Nurse support 4.5 (4.25, 4.74) n=193 3.47(3.17, 3.77) 
POWeR+R 
N=244 
Cost (£)  All costs 386 (296, 477) n=244 386(296, 477) 
Medication 215 (150, 279) n=122 107(73, 142) 
GP consultation 63 (53, 73) n=126 33(26, 39) 
Outpatient 
attendance 
530 (375, 684) n=52 113(71, 155) 
Hospital admission 2794 (997, 4591) n=6 69(6, 132) 
Nurse support 12 (11, 13) n=181 9(8, 10) 
Number 
of cases 
Medication usage 3.17 (2.8, 3.55) n=122 1.59(1.31, 1.86) 
GP consultation 2.55 (2.2, 2.91) n=127 1.33(1.08, 1.57) 
Outpatient 
attendance 
3.92 (2.78, 5.07) n=52 0.84(0.52, 1.15) 
Hospital admission 1.33 (0.48, 2.19) n=6 0.03(0, 0.06) 
Nurse support 4.25 (4.05, 4.46) n=181 3.16(2.88, 3.43) 
Notes: All costs comprise the total of all costs incurred. The main components of all costs were GP consultations, 
medications, outpatient attendance, hospital admissions and nurse support contacts.  
 
 
 
The intervention cost (under “Nurse Support” in Table 7b) was £17 (15 to 18) in the POWER+F group 
and £9 (8 to 10) in the POWER+R group. Total mean NHS obesity related  cost by arm (“All Costs” in 
Table 7b), including “nurse support” in each intervention arm, was £428 (320 to 537) in the control 
group,  £431 (319 to 543) in the POWeR+ Face-to Face and lower in the POWeR+Remote arm at £386 
(296 to 477).  If bootstrapping is used these estimates are £424 (338, 515) in the control group,  £447 
(358, 544)  in the POWeR+ Face-to Face and lower in the POWeR+Remote arm at £388 (315, 468), with 
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difference to the control group for POWeR+ Face-to Face of 23 (-105 to 152) and POWeR+Remote -36 
(-154 to 81).  These cost differences were not statistically significant.  
 
 
 
 
 
Cost effectiveness acceptability curves  
 
The cost effectiveness acceptability curves (Figures 2, and 3) for weight loss show the probability of each 
of the comparisons being cost effective in terms of levels of willingness to pay per kilogram lost. These 
put the probability of being cost effective at well over 80% for both interventions compared with the 
control group. There was little difference between the two intervention groups in terms of incremental 
cost per kg lost. 
 
Figure 2 Cost effectiveness acceptability curve of POWeR+F compared with control group based 
on weight loss from baseline (kg) over 12 months  
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Figure 3 Cost effectiveness acceptability curve of POWeR+R compared with control group based 
on weight loss from baseline (kg) over 12 months  
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Appendix 3:  
Sub-group analysis  
Metabolic syndrome: The interaction term for those having the metabolic syndrome at 6 months was 
3.04 (95% CI 0.33, 5.74; p=0.028) for the Face-to-face group and 1.26 (95% CI -1.37, 3.88; p=0.348) for 
the Remote group, i.e. the Face-to-face intervention was more effective in those not having the metabolic 
syndrome, but this was only evident in the short term. At 12 months, the interaction terms were 0.58 (-
2.42, 3.57; p=0.707) for the Face-to-face group and 0.45 (-2.51, 3.41; p=0.765) for the Remote group. 
 
Waist circumference: We originally specified high waist measurements as a possible subgroup but since 
only 5 of the trial cohort had low waist measurements this was not possible. 
 
Choice of diet:  Among participants who initially chose the  low carbohydrate diet compared to a low 
calorie diet:  weight reduction was not significantly greater at 6 months (interaction term -0.77 (-2.09, 
0.56; p=0.258) nor 12 months (-0.46 (-1.95, 0.84; p=0.489); there was no differential effect on lipids; and 
ferritin was slightly higher at 12 months (+24.3,95% CI 0.90 to 47.61, p=0.042).   
 
Analysis using measured weights only: 
 
Table 8.  Complete cases–measured weight only 
 Mean kg (SD) at 6 
months 
Mean Kg (SD) at 
12 months 
Control 101.86 (19.95)  101.02 (18.26)  
Face-to-face 98.58 (17.65)  98.19 (16.10)  
Remote 97.18 (16.67)  99.02 (18.13)  
 
 
Table 9.  Complete cases– estimated differences in weight (kg) compared to monitoring group 
based on measured weight only 
 
 Difference compared to the control group 
 6 months 12 months Over study period 
(repeated measures) 
POWeR+:Face- to- 
face 
-3.20 (-5.00, -1.39; 
p=0.001)  
-1.02  
(-2.27, 0.22; 
p=0.107)  
-1.78 (-2.81, -0.76; 
p=0.001)  
POWeR+: Remote -3.22 (-5.03, 1.41; 
p<0.001)  
-0.96  
(-2.21, 0.29; 
p=0.134)  
-1.60 (-2.63, 0.57; 
p=0.002)  
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Appendix 4. Other secondary measures 
Physical activity: The validated Godin leisure time physical activity questionnaire.  
Food and drink consumption: Using validated brief Food Frequency Questionanires (FFQs) for major 
food groups and also alcohol    
Indices of the metabolic syndrome 3 out of 5 of elevated waist  circumference (<94cm for men, 80 for 
women), TG >=1.7 mmol/l, reduced HDLcholesterol (<1.00 mmol/L in males <1.3 mmol/l in females) BP 
(SPB >130 or diastolic >85, or treatment of high BP) elevated fasting glucose >= 5.6 mmol/l.  Individuals 
with the metabolic syndrome are at particular risk. We  report the number (%) in each group using a 
definition of  3 out of 5 of high measurements30 
Waist: nurses  measured waist midway between the lower ribs and the iliac crests31 and height to allow 
estimation of BMI; fat mass was measured using Tanita scales;  
Blood pressure (BP): Measured 3 times (after 5 min) using a validated OMRON;  
Serum measures: Liver function tests,  serum cholesterol/HDL/LDL/triglyceride (TG) glucose, HbA1c ;  
also ferritin (important to measure due to reducing cereals (a key source of iron) in the low carbohydrate 
diet)   
EuroQol (EQ-5D): the EuroQol provided a measure of quality of life for economic analysis; 
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Table 10a. Liver function tests. Crude data: mean (s.d.) (complete cases) 
 
 ALT Units/l 
(n=329) 
AST Units/l 
(n=303) 
GammaGT  Units/l 
(n=319) 
 Baseline 12 
months 
Baseline 12 
months 
Baseline 12 
months 
Control 30.17 
(16.62)  
30.23 
(15.33)  
30.99 
(14.26)  
29.38 
(10.96)  
39.18 
(35.20)  
38.65 
(31.01)  
POWeR:Face- 
to-face  
31.41 
(17.48) 
27.26 
(14.06)  
31.80 
(13.79) 
27.15 
(9.36)  
43.76 
(46.55)  
35.40 
(26.10)  
POWeR: 
Remote 
31.26 
(17.57) 
27.68 
(16.97)  
30.73 
(13.69)  
27.80 
(9.27)  
38.04 
(30.85)  
40.19 
(40.47)  
 
Table 10b. Liver function tests: estimated differences using multiple imputation compared 
to control group (95 % confidence intervals) 
 
 Liver function – Difference compared to control group at 12 months 
 ALT Units/l 
 
AST units/l 
 
GammaGT Units/l 
 
    
POWeR:Face- 
to-face  
-3.01  
(-6.59, 0.57; p=0.093)  
-2.21 
(-4.77, 0.35; p=0.087)  
-3.06 
 (-9.87, 3.74; p=0.356)  
POWeR: 
Remote 
-2.72  
(-6.08, 0.64; p=0.107)  
-2.02  
(-4.38, 0.34; p=0.090)  
2.03 
 (-5.24, 9.32; p=0.568)  
 
 
 
  
  
 
31 
Table11a. Glucose, HBa1c and Ferritin (mean, s.d.) (complete cases) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table11b. Glucose, HBa1c and Ferritin: estimated difference using multiple imputation 
compared to control group (95 % confidence intervals) 
 
 Difference compared to control group at 12 months 
 Glucose mmol/l 
 
HbA1C mmol/l 
 
Ferritin ug/l 
 
    
POWeR:Face- 
to-face  
-0.20  
(-0.66, 0.26; p=0.375)  
-3.15  
(-8.01, 1.72; p=0.192) 
-4.69 
 (-23.78, 14.40; p=0.616)  
POWeR: 
Remote 
-0.32  
(-0.79, 0.15; p=0.176)  
-2.96 
 (-7.74, 1.83; p=0.213)  
5.86 
 (-12.63, 24.36;     
p=0.516)  
 
 
 
 
 
 
 
 
  
 Glucose mmol/l 
(n=338) 
HbA1C mmol/l 
(n=330) 
Ferritin  ug/l 
(n=362) 
 Baseline 12 
months 
Baseline 12 
months 
Baseline 12 months 
Control 5.68 
(1.88) 
5.88 
(1.94) 
40.49 
(10.42)  
41.09 
(28.68) 
N/A 95.73 
(94.77)  
POWeR:Face- 
to-face  
5.91 
(2.53) 
5.83 
(2.67) 
42.00 
(13.09)  
38.78 
(11.39)  
N/A 95.47 
(84.16)  
POWeR: 
Remote 
5.64 
(1.93)  
5.64 
(1.99) 
40.07 
(11.60)  
38.74 
(12.79) 
N/A 103.78 
(76.24)  
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Table 12a. Cholesterol means (s.d.) (complete cases) 
 
 Total (n=346) 
mmol/l 
HDL (n=348) 
mmol/l 
LDL (n=218) 
mmol/l 
Triglycerides 
(n=286) 
mmol/l 
 Baseline 12 
months 
Baseline 12 
months 
Baseline 12 
months 
Baseline 12 
months 
Control 5.30 
(1.24) 
5.05 
(1.26) 
1.43 
(0.37) 
1.37 
(0.32) 
3.12 
(1.03) 
2.97 
(0.98) 
1.74 
(0.96) 
1.72 
(0.82) 
POWeR:Face- 
to-face  
5.19 
(1.19) 
5.18 
(1.18) 
1.40 
(0.33) 
1.47 
(0.35) 
3.02 
(0.96) 
2.94 
(0.98) 
1.72 
(0.85)  
1.75 
(1.04)  
POWeR: Remote 5.35 
(1.33) 
5.33 
(1.20) 
1.41 
(0.36) 
1.50 
(0.38) 
3.11 
(1.05) 
3.08 
(1.10) 
1.89 
(1.59)  
1.78 
(1.49) 
 
Table 12b. Cholesterol: estimated differences using multiple imputation compared with the 
control group 
 
 Cholesterol – Difference compared to the control group at 12 months 
 Total  
mmol/l 
HDL  
mmol/l 
LDL  
mmol/l 
Triglycerides  
mmol/l 
POWeR:Face- 
to-face  
0.11 (-0.92, 
0.31; p=0.270)  
0.08 (0.02, 
0.15; p=0.010)  
0.01 (-0.19, 
0.22; p=0.894)  
0.03 (-0.28, 
0.34; p=0.826)  
POWeR: 
Remote 
0.14 (-0.08, 
0.35; p=0.204)  
0.10 (0.03, 
0.17; p=0.006)  
0.06 (-0.16, 
0.28; p=0.572)  
0.01 (-0.30, 
0.32; p=0.937)  
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Table 13a Body fat percentage and blood pressure mean(s.d.) (complete cases) 
 
 Body fat percentage  
(n=454) 
SBP (n=494) 
mm Hg 
DBP (n=494) 
mm Hg 
 Baseline 12 months Baseline 12 months Baseline 12 months 
Control 43.59 (7.08)  42.71 
(7.20)  
133.78 
(17.84)  
133.11 
(18.61)  
81.17 (10.64)  79.10 
(10.79)  
POWeR:Face- to-face  43.86 (8.00) 41.40 
(8.81)  
132.28 
(15.81)  
133.31 
(15.70)  
80.97 (9.37)  79.89 
(9.20)  
POWeR: Remote 42.18 (7.79)  40.53 
(8.42)  
134.17 
(17.00)  
132.11 
(17.08)  
80.71 (10.00)  78.92 
(9.710  
 
Table 13b Estimated differences in body fat percentage and systolic (SBP) and diastolic 
(DBP) blood pressure using multiple imputation compared with the control group  
 Body fat percentage   Blood Pressure   
  SBP mm Hg DBP mm Hg 
    
POWeR:Face- 
to-face  
-0.96 (-1.83, -0.08; 
p=0.033)  
0.05 (-2.76, 2.86; 
p=0.973)  
0.67 (-1.12, 2.46; p=0.461)  
POWeR: 
Remote 
-0.53 (-1.47, 0.42; 
p=0.274)  
-2.72 (-5.56, 0.12; 
p=0.061)  
0.02 (-1.64, 1.68; p=0.979)  
 
Table 14. Comparison of weights (Kg) according to diet chosen by the participant 
(complete cases) 
 Mean Kg (SD) at 
baseline (n=510) 
Mean KG (SD) at 6 
months (n=303) 
Mean Kg (SD) at 12 
months (n=392) 
Low calorie diet 102.68 (17.35)  98.12 (17.00)  99.25 (17.65)  
Low carbohydrate 
diet 
102.57 (18.00)  97.30 (17.86)  98.37 (17.46)  
 
Table 15. Physical activity – Godin questionnaire at 12 months(complete cases) 
 
 Median physical 
activity score 
(n=348) 
Difference compared to 
control group 
Control group  20 (11,33)  
POWeR+F  25 (12,41) 2.49  
(-2.72, 7.70; p=0.348)  
POWeR+R  21 (13,45) -0.90  
(-5.97, 4.17; p=0.728)  
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Table 16a Mean portions (s.d.) of foods eaten per day (complete cases) 
 
 Control Power Face-to-Face Power Remote 
 Baseline 12 months Baseline 12 months Baseline 12 months 
Sweets 
 
1.14 (1.33)  0.89 (0.87)  1.39 (1.66)  0.71 (0.98)  1.24 (1.61)  0.86 (1.32)  
Cereals 
 
1.92 (1.17)  1.67 (0.98)  2.02 (1.26)  1.45 (0.97)  1.97 (1.43)  1.40 (0.90)  
Fatty Foods 
 
2.72 (1.85)  2.15 (1.67)  2.86 (2.01)  2.06 (1.45)  2.65 (1.83)  1.97 (1.32)  
Salty snacks 
 
0.33 (0.62)  0.19 (0.31)  0.33 (0.54)  0.16 (0.23)  0.31 (0.54)  0.15 (0.22)  
Sweet drinks 
 
0.49 (1.20)  0.22 (0.59)  0.38 (0.88)  0.11 (0.30)  0.48 (1.17)  0.24 (0.63)  
Fruit and 
veg 
 
3.70 (2.28)  4.63 (2.70) 4.02 (2.57)  4.46 (2.55)  3.85 (2.22)  4.63 (2.40)  
Low fat 
dairy 
1.29 (1.44)  1.23 (1.36)  1.64 (1.51)  1.45 (1.53)  1.43 (1.64)  1.53 (1.54)  
High to low 
fat ratio 
 
2.66 (8.27)  1.54 (8.00)  1.52 (6.41)  1.43 (5.53)  2.39 (7.74)  1.39 (4.59)  
 
 
Table 16b Estimated differences in mean (SD) portions of foods eaten per day  (imputed 
data) 
  
   
Difference compared to control group at 12 months 
 Sweets Cereals Fatty 
Foods 
Salty 
snacks 
Sweet drinks Fruit and 
veg 
Low fat dairy 
Power+F -0.18 
 (-0.37, 0.02; 
p=0.072)  
-0.21 
 (-0.44, 
0.02; 
p=0.072)  
-0.06  
(-0.40, 
0.28; 
p=0.722)  
-0.03 
 (-0.09, 
0.03; 
p=0.357)  
-0.09  
(-0.22, 0.04; 
p=0.165)  
-0.04 
 (-0.67, 
0.58; 
p=0.888)  
0.14  
(-0.21, 0.48; 
p=0.432)  
Power+R  -0.13  
(-0.32, 0.06; 
p=0.161)  
-0.23 
 (-0.46, 
0.01; 
p=0.057)  
-0.19 
 (-0.52, 
0.15; 
p=0.270)  
-0.04  
(-0.09, 
0.02; 
p=0.203)  
0.02  
(-0.10, 0.14; 
p=0.769)  
0.17  
(-0.43, 
0.76; 
p=0.570)  
0.27  
(-0.09, 0.64; 
p=0.138)  
 
 
Table 17. Mean EQ5D scores over 12 months in each group based on complete data 
 
Groups Time Mean score in EQ5D 
(SD), n 
95%CI for Mean 
POWeR+F  
N=267 
Baseline 0.824 (0.169) n =267 (0.804, 0.845) 
months 0.823 (0.207) n=169 (0.791, 0.854) 
12 months 0.82 (0.207) n=139 (0.786, 0.855) 
POWeR+R:  
N=267 
Baseline 0.816 (0.212) n=267 (0.759, 0.841) 
6 months 0.822 (0.2337) n=177 (0.764, 0.857) 
Baseline 0.811 (0.253)  n=151 (0.742, 0.851) 
Control group:  
N=276 
Baseline 0.786 (0.232) n=276 (0.813, 0.814) 
6months 0.799 (0.234) n=168 (0.829, 0.835) 
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12 months 0.783 (0.239) n=134 (0.82, 0.824) 
Table 18 EQ5D changes using bootstrap methods in imputed data 
 
  QALYs Difference  (vs. control) 
Control 
0.791 (0.769, 0.813) 
 
POWeR+F 
0.823 (0.805, 0.841) 0.032 (0.003, 0.059) 
POWeR+R 
0.809 (0.787, 0.83) 0.017 (-0.014, 0.048) 
POWeR+F vs. POWeR+R  
0.014 (-0.013, 0.042) 
  QALYs adjusted  baseline 
QoL 
Difference  (vs. control) 
Control 
0.005 (-0.007, 0.018) 
 
POWeR+F 
-0.002 (-0.013, 0.009) -0.007 (-0.024, 0.009) 
POWeR+R 
-0.008 (-0.02, 0.004) -0.013 (-0.031, 0.004) 
POWeR+F vs. POWeR+R  
0.006 (-0.01, 0.023) 
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